Medscape InDiscussion: Schizophrenia

Podcast autorstwa Medscape

12 Odcinki

S2 Episode 6: Is MDMA a Potential Treatment for Negative Symptoms of Schizophrenia? Exploring Stigma and Strategies to Alleviate Symptoms
Opublikowany: 20.07.2023
S2 Episode 5: First-Episode Schizophrenia: The Importance of Engaging and Educating Patients and Their Families in Treatment
Opublikowany: 21.06.2023
S2 Episode 4: Common and Commonly Unrecognized: Clinical High-risk Syndrome, Psychosis, and Schizophrenia
Opublikowany: 23.05.2023
S2 Episode 3: Psychiatric Comorbidity in Schizophrenia: Assessing Patients and the Impact on Treatment Decisions and Outcomes
Opublikowany: 19.04.2023
S2 Episode 2: Long-Acting Injectables and Schizophrenia: Mitigating the Risk for Relapse and Rehospitalization
Opublikowany: 22.03.2023
S2 Episode 1: Treatment-Resistant Schizophrenia: Detection, Management, and the Importance of Early Initiation of Treatment
Opublikowany: 22.03.2023
S1 Episode 6: Relapse in Schizophrenia: Why It Occurs, How Often It Occurs, and What We Can Do About It
Opublikowany: 7.12.2022
S1 Episode 5: Neuroimaging in Schizophrenia: What Have We Learned?
Opublikowany: 9.11.2022
S1 Episode 4: How Can We Assess Cognitive Functioning in Patients With Schizophrenia? And What Can We Do About It?
Opublikowany: 5.10.2022
S1 Episode 3: What New Antipsychotic Drugs Are Available for Schizophrenia? What Drugs Are Under Development? And What Do They Potentially Offer?
Opublikowany: 13.09.2022
S1 Episode 2: Antipsychotics in Schizophrenia: Effectiveness and Optimal Dosing
Opublikowany: 2.08.2022
S1 Episode 1: What Are the Major Metabolic and Neurologic Risks Associated With Antipsychotic Medications?
Opublikowany: 2.08.2022

1 / 1

Listen to Medscape InDiscussion: Schizophrenia, a podcast series where thought leaders and clinical experts share their diverse insights and practical ideas for optimizing patient care. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984480). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Visit the podcast's native language site

12 Odcinki

S2 Episode 6: Is MDMA a Potential Treatment for Negative Symptoms of Schizophrenia? Exploring Stigma and Strategies to Alleviate Symptoms

S2 Episode 5: First-Episode Schizophrenia: The Importance of Engaging and Educating Patients and Their Families in Treatment

S2 Episode 4: Common and Commonly Unrecognized: Clinical High-risk Syndrome, Psychosis, and Schizophrenia

S2 Episode 3: Psychiatric Comorbidity in Schizophrenia: Assessing Patients and the Impact on Treatment Decisions and Outcomes

S2 Episode 2: Long-Acting Injectables and Schizophrenia: Mitigating the Risk for Relapse and Rehospitalization

S2 Episode 1: Treatment-Resistant Schizophrenia: Detection, Management, and the Importance of Early Initiation of Treatment

S1 Episode 6: Relapse in Schizophrenia: Why It Occurs, How Often It Occurs, and What We Can Do About It

S1 Episode 5: Neuroimaging in Schizophrenia: What Have We Learned?

S1 Episode 4: How Can We Assess Cognitive Functioning in Patients With Schizophrenia? And What Can We Do About It?

S1 Episode 3: What New Antipsychotic Drugs Are Available for Schizophrenia? What Drugs Are Under Development? And What Do They Potentially Offer?

S1 Episode 2: Antipsychotics in Schizophrenia: Effectiveness and Optimal Dosing

S1 Episode 1: What Are the Major Metabolic and Neurologic Risks Associated With Antipsychotic Medications?